GeneTex
United States (US)

DR5 peptide

Cat No. GTX28449

Application Blocking
Species Human
APPLICATION

Application Note

The peptide is used for blocking the activity of DR5 (CT) (GTX28416). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity.
PROPERTIES

Form

Liquid

Buffer

PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide

Storage

Store the peptide at -20˚C, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Tnf Receptor Superfamily Member 10B,Cd262,Dr5,Killer,Killer/Dr5,Trail-R2,Trailr2,Trick2,Trick2A,Trick2B,Trickb,Ztnfr9,Tnfrsf10B

Cellular Localization

Cell Membrane

Background

Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain.

Research Area

Package List Price ($)
$ 179